IMMUNOSUPPRESSIVE POTENTIAL OF PERIPHERAL REGULATORY T-LYMPHOCYTES IN THE PROCESS OF TUMOR PROGRESSION IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMAS
PDF (Русский)

Keywords

METASTATIC SOFT TISSUE SARCOMAS
REGULATORY T-LYMPHOCYTES
IMMUNOSUPPRESSION
CCL2
CCR4
CCR10
NRPL
NRP-1

How to Cite

Pipia, N., Baldueva, I., Danilova, A., Avdonkina, N., Novik, A., Nekhaeva, T., Gafton, G., & Yemelyanova, N. (2018). IMMUNOSUPPRESSIVE POTENTIAL OF PERIPHERAL REGULATORY T-LYMPHOCYTES IN THE PROCESS OF TUMOR PROGRESSION IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMAS. Voprosy Onkologii, 64(3), 400–407. https://doi.org/10.37469/0507-3758-2018-64-3-400-407

Abstract

In tumor microenvironment the self-maintenance condition of T-regulatory lymphocytes (Treg) are created by tumor cells due to the production of vascular endothelial growth factor VEGF and chemokine CCL2. In the present work there was evaluated the quantitative content of these proteins in cultured cell supernatants of metastatic soft tissue sarcomas (STS) as well as characterized the immunophenotype of peripheral blood Treg by flow cytometry. The study included 35 patients who received treatment at the N.N. Petrov National Medical Research Center of Oncology. For the study- samples of metastatic tumor were taken to obtain sarcoma cell culture and samples of peripheral blood of patients in the absence of tumor growth (stable disease-SD) or disease progression (PD). The statistically significant differences were found in the quantitative content of CCR10+Treg (9.1 % and 4.5 %, respectively, p=0.001), CCR4+Treg (10 % and 3.3 %, respectively, p=0.001), neuropilin-1 (Nrp1+) Treg (6 % and 4.5 %, respectively, p=0.021) in patients with PD and SD. A direct correlation of high strength was found between production of VEGF, CCL2 by metastatic STS cells and expression of Nrp1 (r=0.93, p=0.001), VEGFR-2(r=0.88, p=0.007), CCR4(r=0.81, p=0.024) by Treg cells. Statistically significant differences in the CCR10+Treg (9.5 % and 2.93 %, respectively, p=0.012) and CCR4+Treg (68, 3 % and 3.95 %, respectively, p=0.007) were detected in the group of patients with liposarcoma and synovial sarcoma. Thus in patients with metastatic STS - there was directional chemotaxis of Treg into tumor microenvironment providing the creation of tumor-induced tolerance, which could be associated with DP. The revealed regularities could be used to plan adjuvant and palliative treatment of STS patients.

https://doi.org/10.37469/0507-3758-2018-64-3-400-407
PDF (Русский)

References

Как описывать статистику в медицине. Аннотированное руководство для авторов, редакторов и рецензентов / Т.А. Ланг, М. Сесик; пер. с англ. под ред. В.П. Леонова. - М.: Практическая медицина, 2011. - 480 с.

Хайдуков С.В., Зурочка А.В., Тотолян А.А. и др. Основные и малые популяции лимфоцитов периферической крови человека и их нормативные значения (методом проточного цитометрического анализа) // Медицинская иммунология. - 2009. - Т. 11. -№ 2-3. - С. 227-238.

Bohling S.D., Allison K.H. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target // Mod Pathol. - 2008. - Vol. 21(12). - P. 1527-1532.

Bruder D., Probst-Kepper M., Westendorf A.M. et al. Neuropilin-1: a surface marker of regulatory T cells // Eur. J. Immunol. - 2004. - Vol. 34(3). - P. 623-630.

Chang A.L., Miska J., Wainwright D.A. et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells // Cancer Res. - 2016. - Vol. 76(19). - P. 5671-5682. - CAN-16-0144. DOI: 10.1158/0008-5472

Chaudhary B., Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting //Vaccines (Basel). - 2016. - Vol. 4(3). - P.pii E28-53.

Chaudhary B., Khaled YS., Ammori B.J., Elkord E. Neuropilin 1: function and therapeutic potential in cancer // Cancer Immunol. Immunother. - 2014. - Vol. 63(2). - P. 81-99.

Chen L., Liu X., Zhang H.-Y et al. Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival // Oncotarget. - 2014. - Vol. 5(16). - P. 6576-6583.

DeLeeuw R.J., Kost S.E., Kakal J.A., Nelson B.H. The prognostic value of FoxP3 tumor-infiltrating lymphocytes in cancer: A critical review of the literature // Clin. Cancer Res. - 2012. - Vol. 18. - P. 3022-3029.

Facciabene A., Peng X., Hagemann I.S. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells // Nature. - 2011. - Vol. 475(7355). - P. 226-230.

Hansen W., Hutzler M., Abel S. et al. Neuropilin 1 deficiency on CD4 Foxp3 regulatory T cells impairs mouse melanoma growth // J. Exp. Med. - 2012. - Vol. 209(11). - P. 2001-2016.

Ishida T., Ishii T, Inagaki A. Specific recruitment of СС chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege // Cancer Res. - 2006. - Vol. 66(11). - P. 5716-5722.

Kimpfler S., Sevko A., Ring S. et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25 Foxp3 regulatory T cells in lymphoid organs // J. Immunol. -2009. - Vol. 183(10). - P. 6330-6337.

Kitamura, Qian B.Z., Soong D. et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages // J. Exp. Med. - 2015. - Vol. 212. - P. 1043-1059.

Leffers N., Gooden M.J, de Jong R.A. et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer // Cancer Immunol. Immunother. - 2009. - Vol. 58. - P. 449-459.

Li B., Lalani A.S., Harding T.C. et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy // Clin Cancer Res. - 2006. - Vol. 12(22). - P. 6808-6816.

Long K.B., Gladney W.L., Tooker G.M. et al. IFNgamma and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma // Cancer Discov. - 2016. - Vol. 6. - P. 400-403.

Ondondo B., Jones E., Godkin A., Gallimore A. Home sweet home: The tumor microenvironment as a haven for regulatory T cells // Front. Immunol. - 2013. - Vol. 16(4). - Article:197. - 9 p.

Overacre A., Delgoffe G., Vignali D. Neuropilin-1 enforces Treg stability and function in the tumor microenvironment // J. Immunol. - 2014. - Vol. 192 (1 Supplement). - P. 71.13.

Pena C.G., Nakada Y, Saatcioglu H.D. et al. LKB1 loss promotes endometrial cancer progression via CCL2-de-pendent macrophage recruitment // J. Clin. Invest. - 2015. - Vol. 125. - P. 4063-4076.

Sayour E.J., McLendon P., McLendon R. et al. Increased proportion of FoxP3 regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma // Cancer Immunol. Immunother. - 2015. - Vol. 64. - P. 419427.

Shang B., Liu Y, Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3 regulatory T cells in cancers: A systematic review and meta-analysis // Sci. Rep. - 2015. - Vol. 14 (5). - P. 15179.

Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity // Int. Immunol. -2016. - Vol. 28(8). - P. 401-409.

Tao H., Mimura Y, Aoe K.et al. Prognostic potential of FOXP3 expression in non-small cell Lung Cancer cells combined with tumor-infiltrating regulatory T cells // Lung Cancer. - 2012. - Vol. 75. - P. 95-101.

Terme M., Pernot S., Marcheteau E. et al. VEGFA-VEGFR pathway blockade inhibits tumorinducedregulatory T-cell proliferation in colorectal cancer // Cancer Res. - 2013. - Vol. 73(2). - P. 539-549.

Turk M.J. Regulatory T cells and cancer / In: Gabrilovich D.I., Hurwitz A.A., editors. Tumor-induced immune suppression. Mechanisms and therapetic reversal. - New York: Springer; 2014. - p. 1-37.

Ward-Hartstonge K.A., Kemp R.A. Regulatory T-cell heterogeneity and the cancer immune response // Clin. Translational. Immunol. - 2017. - Vol. 6. - P. e154.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2018